title: Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome.
abstract: Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral regression of corneal neovascularization.
authors.affiliation: Miriam Hyman Children's Eye Care Centre, L V Prasad Eye Institute, Bhubaneswar, Orissa, India.
authors.forename: Siddharth
authors.initials: S
authors.lastname: Kesarwani
authors.forename: Srikant Kumar
authors.initials: SK
authors.lastname: Sahu
authors.forename: Soumyava
authors.initials: S
authors.lastname: Basu
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D013262:Stevens-Johnson Syndrome / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab